Test Price
3,500 AED✅ Home Collection Available
Eukaryotic mRNA Sequencing & Reference-Based Analysis (Low Input) in UAE — DHA Licensed | 3,500 AED
Executive Summary & Core Metrics
Low-Input mRNA Sequencing with DHA licensed laboratory, achieving 99.9% diagnostic sensitivity, ISO-certified cold chain transport, and telephonic post-test clinical guidance.
- ✓Accuracy Guarantee – 99.9% diagnostic sensitivity through ISO 9001:2015 certified processing (Cert: INT/EGQ/2509DA/3139) and SMART-Seq v4 ultra-low input chemistry.
- ✓Premium Logistics – Paid hospital-grade home collection with ISO certified cold‑chain transport & VIP mobile phlebotomy across all UAE emirates (8 AM – 11 PM).
- ✓Clinical Guidance – Telephonic post‑test clinical guidance in result interpretation with a board‑certified specialist to transform complex transcriptomic data into actionable insights.
- ✓Insurance & Billing – Direct insurance billing verification via WhatsApp at +971 54 548 8731. We handle pre‑approval from all major UAE networks.
Test Overview & Methodology
Overview
This low-input eukaryotic mRNA sequencing test delivers whole‑transcriptome profiling from minimal input material (50 pg – 10 ng of total RNA) suitable for oncology, rheumatology, and advanced biomedical research. It replaces older, less sensitive RNA‑seq approaches with a clinical‑grade, DHA‑aligned protocol.
| Feature | Our Low‑Input mRNA Test | Closest Alternative (Standard RNA‑seq) |
|---|---|---|
| Sample Input | 50 pg – 10 ng total RNA (ultra‑low) | ≥ 100 ng total RNA (polyA‑selection) |
| Library Prep Method | SMART‑Seq v4 (full‑length transcript coverage) | Standard polyadenylated RNA capture |
| Sensitivity | High – detects lowly expressed genes & isoforms | Moderate – less effective with degraded/limited RNA |
| Turnaround Time | 8 weeks (expedited reporting available) | 10–12 weeks |
| Price (AED) | 3,500 | 4,200 + |
| Clinical & Research Utility | Oncogenomic profiling, rheumatic signatures, biomarker discovery – DHA compliant | General transcriptomics, limited low‑input performance |
Physician Insight & Safety Protocols
“As a consultant medical geneticist, I understand the anxiety that comes with waiting for advanced genomic results. We ensure each mRNA transcriptome report is meticulously correlated with your clinical picture and history. This low‑input test opens a window to disease mechanisms, but it must always be interpreted by a specialist who knows you fully.” — Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA ID: 9294403
Advisory – Medication & Treatment Continuity
Do not discontinue or alter any prescribed medication without consulting your treating physician. This test provides complementary molecular information and is not a stand‑alone treatment directive. Always follow your doctor’s guidance for medication management and therapeutic decisions.
Exclusion Criteria & Emergency Red Flags
- Sample insufficiency: Total RNA quantity below 50 pg or severe RNA degradation indicated by RIN ≤ 4.
- Informed consent: For minors (<18 years), explicit consent as per Federal Decree-Law No. 4 of 2016 on Medical Liability and Federal Law No. 2 of 2019 is mandatory; unconsented samples will be rejected.
- Pre‑analytical error: Samples collected without RNase‑free technique or incorrect preservative (non‑PAXgene/RNAlater) may yield non‑reportable results.
- Red flag findings: Discovery of a medically actionable mutation (e.g., BRCA1/2, TP53) will be communicated urgently to the ordering physician. Do not self‑interpret pathogenic or likely pathogenic results – immediate specialist consultation is required.
Patient FAQ & Clinical Guidance
1. What exactly does low‑input mRNA sequencing detect, and why is it better for small samples?
Snippet: This advanced genomic test precisely measures gene expression levels from extremely small biological specimens, enabling early detection of disease signatures without the need for large tissue biopsies.
It captures the full profile of messenger RNA molecules in a sample, revealing which genes are turned on or off. Because it works with only 50 picograms of RNA, it is ideal for fine‑needle aspirates, rare cell populations, or archived samples where standard RNA‑seq fails.
2. How should I prepare for the test, and are there any dietary or medication restrictions?
Snippet: No fasting or dietary restrictions are required; simply ensure the blood or tissue sample is collected by a certified phlebotomist using the special RNA preservation tube we provide.
We supply PAXgene Blood RNA tubes or RNAlater preservatives free of charge. Continue all prescribed medications unless your doctor advises otherwise. Avoid touching the inner tube cap to prevent RNase contamination. The collection takes less than 10 minutes at home or our facility.
3. When will I get the results and who will explain them to me?
Snippet: You will receive your comprehensive transcriptomic report in 8 weeks; a board‑certified specialist will then guide you telephonically through every significant finding in plain language.
The report includes differential gene expression tables, pathway analysis, and clinical annotations. To book your post‑test consultation, simply message us on WhatsApp +971 54 548 8731. All data handling adheres to UAE PDPL and international GDPR standards for your privacy.
UAE Regulatory & Data Privacy Adherence
All laboratory services and data handling procedures strictly comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety and patient consent protocols are aligned with Federal Decree-Law No. 4 of 2016 on Medical Liability. Your genomic data is encrypted end‑to‑end and never shared without explicit written authorization.
Clinical & Logistical Metadata
| Test Name | Eukaryotic mRNA Sequencing & Reference-Based Analysis (Low Input) |
| Price (AED) | 3,500 AED |
| Turnaround Time | 8 weeks (expedited reporting available) |
| Sample Type / Matrix | Whole blood (PAXgene Blood RNA tube) or tissue (RNAlater) |
| Methodology Used | SMART‑Seq v4 (full‑length transcript coverage) |
| ICD-10-CM Code | Z12.9 (Encounter for screening for malignant neoplasm, unspecified) |
| LOINC Code | 73487-2 (mRNA expression profiling) |
| DHA Facility License & Laboratory Address | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians